TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05345093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ialuxid gel
Description: Ialuxid® Gel is intended for topical external use. It is formulated with the appearance of white to pale yellow coloured consistent gel.~Ialuxid® Gel will be used for 8 weeks, 2-3 times a day.
Study: NCT04822636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based mental health navigation
Description: Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
Study: NCT04354025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: -Ara-C (dose: 2000mg/m\^2 per dose) will be given daily for a total of 5 doses administered as IV infusion over 3 hours, starting the same day as fludarabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: -Filgrastim (dose: 5 mcg/kg per dose to a maximum of 300 mcg) will be given subcutaneously daily for a total of 5 doses starting the same day as fludarabine and ara-C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: -IL-2 will be administered subcutaneously at a dose of 1 million units/m2 every other day from Day 0 to Day +12 (7 doses total).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Leukapheresis
Description: -Donor only
Study: NCT05770414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Make the Connection® Online Program
Description: Make the Connection® (MTC) is an evidence-based parenting program offered by Strong Minds Strong Kids, Psychology Canada. Recently, the MTC program has been adapted to an online platform to help increase scalability and accessibility across Canada. The online modality is self-administered by caregivers and consist of 8 weekly, 15-minute modules.~MTC is an attachment-focused, evidence-informed, parent training program that is designed to support the development of positive parent-child relationships by teaching caregivers to understand their infant's cues. The overarching goal of the program is to enhance parental attitudes and cognitions towards their infants, which have been shown to be associated with sensitive parenting behaviour, and in turn, secure child attachment. Ultimately, by improving parenting skills and attitudes, the program seeks to support secure infant attachment.
Study: NCT05690633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Description: Noninvasive method of measuring the saturation of oxygen in the blood.
Study: NCT05980000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab is administered at a dose of 10 mg/kg over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered at a flat dose of 200 mg over 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab is administered at a flat dose of 200 mg over 30 minutes.
Study: NCT05706467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive high-frequency oscillatory ventilation
Description: Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive continuous positive airway pressure ventilation
Description: Non-invasive positive airway pressure ventilation is carried out through non-invasive ventilator.
Study: NCT06453551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN501 - Dose 1
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN501 - Dose 2
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN501 - Dose 3
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN501 - Dose 4
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN501 - Dose 5
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN501 - Dose 6
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN501 - Dose 7
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN501 - Dose 8
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Study: NCT04834986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with Lenvatinib
Description: Pre-operation: Tislelizumab, 200mg, iv,d1,q3w, 2-4 cycles; Lenvatinib,8mg/kg,po,qd,d1-d84.~Operation Postoperation: 4-8 weeks after surgery, Tislelizumab, 200mg, iv,d1,q3w; Lenvatinib,8mg/kg,po,qd, up to one year.
Study: NCT06159647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liver cancer warning
Description: Participants will view messages about the risk of liver cancer from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colon and rectum cancer warning
Description: Participants will view messages about the risk of colon and rectum cancer from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast cancer
Description: Participants will view messages about the risk of breast cancer from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer (generic, not site-specific)
Description: Participants will view messages about the risk of cancer (not site-specific) from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Addiction and neurological changes
Description: Participants will view messages about the risk of addiction and neurological changes from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypertension
Description: Participants will view messages about the risk of hypertension from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liver damage
Description: Participants will view messages about the risk of liver damage from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harm to fetus
Description: Participants will view messages about the risk of harm to a fetus from alcohol consumption during pregnancy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dementia
Description: Participants will view messages about the risk of dementia from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impaired sleep
Description: Participants will view messages about the risk of impaired sleep from alcohol consumption.
Study: NCT06214156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be given intratumorally， Q2W；
Study: NCT04019119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital intervention
Description: The information group will receive through a mobile application tips to reduce sedentary lifestyle and promote healthy living habits.
Study: NCT04928638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual educational intervention
Description: Educational intervention about the disease, the use of medication and the context of pandemic

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written educational intervention
Description: Educational intervention about the disease, the use of medication and the context of pandemic
Study: NCT05777278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (60 mg/m2, ivgtt, q3w)
Study: NCT04823897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI-001
Description: Dose Escalation Phase: CCI-001 will be administered by intravenous infusion starting at 1.2mg per square metre of body surface area in the first cohort. The dose will be escalated sequentially in subsequent cohorts. The degree of dose escalation between subsequent cohorts will depend on tolerability, as judged by NCI-CTCAE grading. Once the maximum tolerated dose is determined this phase will be complete.~Dose Expansion Phase: cohorts of patients with the following tumour types will be enrolled: transitional cell bladder cancer, pancreaticobiliary adenocarcinomas, gynecologic cancers (ovarian, cervical, endometrial), and lung adenocarcinoma. These patients will be treated at the dose determined in the dose escalation phase.
Study: NCT05056376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Diabetes Prevention Program (dDPP)
Description: The Sweetch app is a hyper-personalized mobile digital coach that provides users with tailored recommendations to promote healthy lifestyle behaviors (150 minutes per week of physical activity, weight reduction, and healthy eating habits) to reduce the risk of type 2 diabetes.~The Sweetch app uses self-tracking and multiple evidence-based persuasive eCoaching strategies. The Sweetch artificial intelligence algorithm delivers just-in-time support and/or adapt recommendations based on the user's response. For example, push notifications will be sent when the algorithm detects that the user is potentially available and able to act upon the recommendation, based on various parameters including location, previous response, calendar availability, and weather, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Coach-based Diabetes Prevention Program (hDPP)
Description: The Human Coach-Based Diabetes Prevention Program will consist of a CDC recognized lifestyle change program. Participants will attend a total of 16 weekly sessions during months 1 to 6 and 6 sessions during months 7 to 12. These group sessions may be delivered in-person at the local program or remotely using video conferencing. During these sessions, participants will receive information about lifestyle change behaviors focusing on weight loss, physical activity, and nutrition from a trained lifestyle coach.
Study: NCT04890834

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard care

Intervention type: OTHER
Group type: OTHER
Intervention: Best Practice
Description: Receive standard care

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Intervention
Description: Participate in yoga sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05048238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: 10 participants with Cutaneous lupus erythematosus (CLE). Consenting individuals meeting all entry criteria will undergo 25 days of treatment with tofacitinib (11 mg orally (PO) daily) with evaluation of UVB-mediated cutaneous apoptosis
Study: NCT06561854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: ICARIA schema :~40mg (20mg for ≥75yr) on day 1, 8, 15, 22 of each cycle plus~IKEMA schema :~20 mg on day 1-2, day 8-9, day 15-16 and day 22-23 of each cycle~For subjects older than 75 years or underweight (BMI \<18.5), the dexamethasone dose may be administered at a total dose of 20 mg weekly.~In both schema (ICARIA or IKEMA), dexamethasone will be administrated up to 2 cycle (Arm 1) or until disease progression (Arm2)
Study: NCT06235892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACROLIMUS
Description: TACROLIMUS 2-3.5 ng/ml
Study: NCT05676489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]MeFAMP PET
Description: Study participants will receive the fluorine-18 labeled system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid (\[F-18\]MeFAMP), for positron emission tomography (PET). Participants in Cohorts 1 and 2 will receive a single administration of the study drug. Participants in cohort 3 will receive 2 administrations of the study drug, once before standard of care radiation therapy for brain metastases and once after.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]MeFAMP PET
Description: Study participants will receive the fluorine-18 labeled system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid (\[F-18\]MeFAMP), for positron emission tomography (PET). Participants in Cohorts 1 and 2 will receive a single administration of the study drug. Participants in cohort 3 will receive 2 administrations of the study drug, once before standard of care radiation therapy for brain metastases and once after.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]MeFAMP PET
Description: Study participants will receive the fluorine-18 labeled system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid (\[F-18\]MeFAMP), for positron emission tomography (PET). Participants in Cohorts 1 and 2 will receive a single administration of the study drug. Participants in cohort 3 will receive 2 administrations of the study drug, once before standard of care radiation therapy for brain metastases and once after.
Study: NCT03807973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Zr-89]Oxine-labeled leukocytes PET/MRI
Description: All study participants will undergo an investigational imaging study using autologous \[Zr-89\]-labeled leukocytes and brain PET/MRI. Participants will undergo a venous blood draw, and the leukocytes in the blood sample will be isolated for labeling using \[Zr-89\]oxine. The labeled leukocytes (7.4- 18.5 megabecquerel (MBq), 200-500 uCi) will be re-injected into the participant followed by brain PET/MRI at 24-48 hours after injection. Participants will be asked to have a second brain imaging study 3-6 days after this injection, but this second imaging study is optional.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Zr-89]Oxine-labeled leukocytes PET/MRI
Description: All study participants will undergo an investigational imaging study using autologous \[Zr-89\]-labeled leukocytes and brain PET/MRI. Participants will undergo a venous blood draw, and the leukocytes in the blood sample will be isolated for labeling using \[Zr-89\]oxine. The labeled leukocytes (7.4- 18.5 megabecquerel (MBq), 200-500 uCi) will be re-injected into the participant followed by brain PET/MRI at 24-48 hours after injection. Participants will be asked to have a second brain imaging study 3-6 days after this injection, but this second imaging study is optional.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Zr-89]Oxine-labeled leukocytes PET/MRI
Description: All study participants will undergo an investigational imaging study using autologous \[Zr-89\]-labeled leukocytes and brain PET/MRI. Participants will undergo a venous blood draw, and the leukocytes in the blood sample will be isolated for labeling using \[Zr-89\]oxine. The labeled leukocytes (7.4- 18.5 megabecquerel (MBq), 200-500 uCi) will be re-injected into the participant followed by brain PET/MRI at 24-48 hours after injection. Participants will be asked to have a second brain imaging study 3-6 days after this injection, but this second imaging study is optional.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Zr-89]Oxine-labeled leukocytes PET/MRI
Description: All study participants will undergo an investigational imaging study using autologous \[Zr-89\]-labeled leukocytes and brain PET/MRI. Participants will undergo a venous blood draw, and the leukocytes in the blood sample will be isolated for labeling using \[Zr-89\]oxine. The labeled leukocytes (7.4- 18.5 megabecquerel (MBq), 200-500 uCi) will be re-injected into the participant followed by brain PET/MRI at 24-48 hours after injection. Participants will be asked to have a second brain imaging study 3-6 days after this injection, but this second imaging study is optional.
Study: NCT05421897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab with Chemotherapy
Description: Rapid infusion of dinutuximab in 4 hours or less
Study: NCT05034783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-HBED-CC-exendin-4
Description: Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) \[68Ga\]Ga-HBED-CC-exendin-4. Tracer doses of \[68Ga\]Ga-HBED-CC-exendin-4 will be used to image lesions of insulinoma by PET/CT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-exendin-4
Description: Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) \[68Ga\]Ga-NOTA-exendin-4. Tracer doses of \[68Ga\]Ga-NOTA-exendin-4 will be used to image lesions of insulinoma by PET/CT.
Study: NCT05462587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVTX-803 (L-Fucose)
Description: L-fucose crystalline powder
Study: NCT04933097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfet2®
Description: Conducting a day hospitalization including analyses:~1. Quantitative muscular analysis by measuring the DEXA of the whole body, the reference method for measuring body compartments and allowing the diagnosis of sarcopenia (IMMA\<7 in men and 5.5 in women)~2. Qualitative muscular analysis:~   * isokinetic measurement of muscular strength carried out on 3 muscle groups using a manual measurement sensor such as Microfet2 ® : quadriceps, triceps brachii, biceps~  * measurement of grip strength using Jamar® equipment validated as recommended by the EWGSOP~  * a walking test to assess the functional impact of sarcopenia and its severity
Study: NCT06593665

Intervention type: DRUG
Group type: OTHER
Intervention: Inrathecal Morphine
Description: Intrathecal preservative free morphine (duramorph) 200 mcg with 7.5mg of hyperbaric bupivacaine placed by a spinal needle prior to induction of general anesthesia (n=71)

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Methadone
Description: Intravenous methadone dosed at 0.2 mg/kg Ideal Body weight up to a maximum dose of 20mg, rounded to the nearest milligram, for all patients given during the induction of general anesthesia (n=71)
Study: NCT05313191

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pencil Beam Scanning Proton Therapy
Description: Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pencil Beam Scanning Proton Therapy
Description: Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pencil Beam Scanning Proton Therapy
Description: Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pencil Beam Scanning Proton Therapy
Description: Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pencil Beam Scanning Proton Therapy
Description: Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pencil Beam Scanning Proton Therapy
Description: Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pencil Beam Scanning Proton Therapy
Description: Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
Study: NCT06381492

Intervention type: DEVICE
Intervention: MRI
Description: MRI using DTI technology

Intervention type: DEVICE
Intervention: MRI
Description: MRI using DTI technology

Intervention type: DEVICE
Intervention: MRI
Description: MRI using DTI technology

Intervention type: DEVICE
Intervention: Ultrasound (US)
Description: Standard US

Intervention type: DEVICE
Intervention: Ultrasound (US)
Description: Standard US

Intervention type: DEVICE
Intervention: Ultrasound (US)
Description: Standard US

Intervention type: DEVICE
Intervention: Neuromuscular electric stimulation (NMES)
Description: Standard NMES

Intervention type: DEVICE
Intervention: Neuromuscular electric stimulation (NMES)
Description: Standard NMES

Intervention type: DEVICE
Intervention: Neuromuscular electric stimulation (NMES)
Description: Standard NMES
Study: NCT06476834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days
Study: NCT06638632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Patients with dementia and care partners will receive an iteration of the decision aid and provide feedback.
Study: NCT04260126

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®) and PDS0101
Description: IV infusion of pembrolizumab 200 mg + two 0.5mL sub-cutaneous injections of PDS0101 administered on Cycle 1, 2, 3, 4 and 12. IV infusion of Pembrolizumab 200 mg monotherapy will be administered Cycles 5 - 11 and 13 - 35.